Aligos Therapeutics Reports Results of Operations in 8-K

What Happened
On August 6, 2026, Aligos Therapeutics, Inc. (ALGS) filed a Form 8-K (Accession No. 0001171843-26-005294) to report results of operations and financial condition. The company issued a press release on that date, which is attached to the 8-K as Exhibit 99.1 and is incorporated by reference under Item 2.02.

Key Details

• Filing date: August 6, 2026; Form 8-K covering Item 2.02 (Results of Operations and Financial Condition).
• Exhibit: Press release dated August 6, 2026 included as Exhibit 99.1.
• Item 9.01 lists the press release as an exhibit and notes the cover page interactive data file is embedded in the Inline XBRL document.
• The 8-K does not report any executive changes or merger activity (no Items 5.02 or 1.01 disclosed).

Why It Matters
This 8-K signals that Aligos has publicly released updated financial results or commentary on its financial condition—information investors use to assess quarterly results, revenue trends, and overall business health. Retail investors should read the attached press release (Exhibit 99.1) for the specific numbers (revenue, net loss/profit, guidance) and any management commentary, since those details can affect the stock and investment decisions. The full exhibit is available on the SEC EDGAR site and often on the company’s investor relations page.